Clinical trials: Metastatic Tumor
PIK3CA Mutation, Solid Tumor, Adult
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
This is a Phase 1, first-in-human, open-label study designed to evaluate the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor…
- Conditions
- PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer
- Trial name
- NCT05759949
- Testing
- RLY-5836, Fulvestrant, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Relay Therapeutics, Inc.
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects with Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT04086758
- Testing
- zolbetuximab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma China, Inc.
Neoplasms
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
- Trial name
- NCT05993299
- Testing
- Letetresgene autoleucel, Cyclophosphamide, Fludarabine
- Where
- 38 sites in United States, Canada and 5 more
- Volunteers
- 7 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Non-small Cell Lung Cancer
A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.
- Trial name
- NCT04951648
- Testing
- Almonertinib, chemotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pancreatic Neoplasms, Metastases, Neoplasm
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas.
- Trial name
- NCT00035035
- Testing
- GEMZAR, ALIMTA
- Where
- 114 sites in United States, Argentina and 16 more
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer
This is a blinded Phase 2 study designed to evaluate the safety and efficacy of inavolisib with bevacizumab and chemotherapy, in participants with metastatic colorectal cancer (mCRC) whose tumors have a PIK3CA mutation.
- Trial name
- INAVO-CRC (NCT07323576)
- Testing
- Inavolisib, Bevacizumab, FOLFOX
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
The purpose of this study is to determine if the combination of enzastaurin and pemetrexed can extend survival time without progression of disease for participants who have advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT00530621
- Testing
- enzastaurin, pemetrexed
- Where
- 25 sites in United States, France and 4 more
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Cancer, Solid Tumor Cancer
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies.
- Conditions
- Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate
- Trial name
- NCT07424547
- Testing
- SYS6043
- Where
- 5 sites in United States
- Volunteers
- 386 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Soft Tissue Sarcoma
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)
The purpose of the study is to evaluate the efficacy and safety of eribulin mesylate in subjects with soft tissue sarcoma who received at least one standard chemotherapy (an anthracycline or an ifosfamide monotherapy or a…
- Trial name
- NCT01458249
- Testing
- eribulin mesylate
- Where
- 12 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Eisai Co., Ltd.
Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
study evaluates EB-NK-301, an investigational off-the-shelf allogeneic CAR-NK cell product targeting TROP2, in adults with advanced or metastatic solid tumors that express TROP2 and have progressed after standard therapy.
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
- Trial name
- SOLID-NK (NCT07589530)
- Testing
- EB-NK-301, Fludarabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Solid Tumors
Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour
The main objective of the trial is to document the safety and antivascular effect of escalating doses of NGR-hTNF, from 60 mcg/sqm to 325 mcg/sqm, in patients affected by advanced or metastatic solid tumors not amenable of…
- Trial name
- NCT00878111
- Testing
- NGR-hTNF
- Where
- Italy
- Volunteers
- 48 people
- Sponsor
- AGC Biologics S.p.A.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
This study is a retrospective real-world study to evaluate the efficacy of Osimertinib for patients with advanced or metastatic EGFR 20exon insertion mutation (20ins) Non-Small Cell Lung Cancer.
- Trial name
- NCT05513664
- Testing
- Osimertinib
- Where
- 24 sites in China
- Volunteers
- 80 people
- Sponsor
- Shanghai JMT-Bio Inc.
Pancreatic Neoplasms, Melanoma
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
In this national Phase I dose-escalation study the safety and tolerability of AP 12009 is evaluated in adult patients with advanced tumors known to overproduce TGF-β2, who are not or no longer amenable to established therapies.
- Conditions
- Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms
- Trial name
- NCT00844064
- Testing
- AP 12009
- Where
- 10 sites in Germany
- Volunteers
- 62 people
- Sponsor
- Isarna Therapeutics GmbH
Non Small Cell Lung Carcinoma NSCLC
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of…
- Trial name
- NEPTUNE (NCT02542293)
- Testing
- Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin
- Where
- 210 sites in United States, Argentina and 27 more
- Volunteers
- 953 people
- Sponsor
- AstraZeneca
Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced…
- Trial name
- NCT06724016
- Testing
- HM16390, pembrolizumab
- Where
- 8 sites in United States, South Korea
- Volunteers
- 292 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Lung Cancer
Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)
The purpose of this study is to determine if the addition of motexafin gadolinium (study drug) to standard treatment with docetaxel will improve the response rate in patients with non-small cell lung cancer.
- Trial name
- NCT00373204
- Testing
- Motexafin Gadolinium
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Pharmacyclics LLC.
Locally Advanced or Metastatic Solid Tumors, NSCLC
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma
- Trial name
- NCT05581004
- Testing
- Enzelkitug, Atezolizumab, Pembrolizumab
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Genentech, Inc.
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body.
- Conditions
- Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
- Trial name
- NBM-BMX-UM (NCT07136181)
- Testing
- NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novelwise Pharmaceutical Corporation
Osteoarthritis, Hip, Coxarthrosis; Primary
Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®)
The infection rate after Total Hip Arthroplasty (THA) is about 1%. It is a serious condition, with high morbidity, sometimes fatal, requiring costly treatment.
- Conditions
- Osteoarthritis, Hip, Coxarthrosis; Primary, Coxarthrosis; Secondary, Osteonecrosis; Aseptic, Idiopathic
- Trial name
- NCT03113981
- Testing
- Total Hip Arthroplasty
- Where
- 7 sites in France
- Volunteers
- 340 people
- Sponsor
- Societe ACTIVBIOMAT
Non-small Cell Lung Cancer
H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC
This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with EGFR mutation-positive locally…
- Trial name
- NCT05552781
- Testing
- H002 capsule
- Where
- 8 sites in China
- Volunteers
- 76 people
- Sponsor
- RedCloud Bio
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.